University of New Mexico Health Sciences Center
A year into the COVID-19 pandemic, mass vaccinations have begun to raise the tantalizing prospect of herd immunity that eventually curtails or halts the spread of SARS-CoV-2. But what if herd immunity is never fully achieved – or if the mutating virus gives rise to hyper-virulent variants that diminish the benefits of vaccination?
Those questions underscore the need for effective treatments for people who continue to fall ill with the coronavirus. While a few existing drugs show some benefit, there’s a pressing need to find new therapeutics.
Led by The University of New Mexico’s Tudor Oprea, MD, PhD, scientists have created a unique tool to help drug researchers quickly identify molecules capable of disarming the virus before it invades human cells or disabling it in the early stages of the infection.
New computational tool helps screen molecules for their potential COVID-fighting properties
A year into the COVID-19 pandemic, mass vaccinations have begun to raise the tantalizing prospect of herd immunity that eventually curtails or halts the spread of SARS-CoV-2. But what if herd immunity is never fully achieved - or if the mutating virus gives rise to hyper-virulent variants that diminish the benefits of vaccination?
Those questions underscore the need for effective treatments for people who continue to fall ill with the coronavirus. While a few existing drugs show some benefit, there s a pressing need to find new therapeutics.
Led by The University of New Mexico s Tudor Oprea, MD, PhD, scientists have created a unique tool to help drug researchers quickly identify molecules capable of disarming the virus before it invades human cells or disabling it in the early stages of the infection.
Read Time:
A year into the COVID-19 pandemic, mass vaccinations have begun to raise the tantalizing prospect of herd immunity that eventually curtails or halts the spread of SARS-CoV-2. But what if herd immunity is never fully achieved - or if the mutating virus gives rise to hyper-virulent variants that diminish the benefits of vaccination?
Those questions underscore the need for effective treatments for people who continue to fall ill with the coronavirus. While a few existing drugs show some benefit, there s a pressing need to find new therapeutics.
Led by The University of New Mexico s Tudor Oprea, MD, PhD, scientists have created a unique tool to help drug researchers quickly identify molecules capable of disarming the virus before it invades human cells or disabling it in the early stages of the infection.
Insilico Medicine discovers novel preclinical candidate to address idiopathic pulmonary fibrosis
Insilico Medicine has demonstrated a breakthrough in Artificial Intelligence ( AI ) and drug discovery linking together generative chemistry and biology for the first time to discover a novel preclinical candidate addressing idiopathic pulmonary fibrosis ( IPF ) and be validated with multiple human cell and animal model experiments.
Often found implicated in a wide range of diseases and multiple organs such as lung, liver and kidney, IPF addresses a very broad medical need that affects hundreds of thousands of individuals worldwide.
The pinnacle of the deep learning revolution can be pinged to 2014 when deep learning systems accelerated by NVIDIA GPUs and AI software started outperforming humans in image recognition and generative adversarial networks were invented. It is also the year when we started the company. In 2016 we demonstrated that a deep learning system can identify a n